$207 Million is the total value of Iguana Healthcare Management, LLC's 59 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 131.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Buy | CELGENE CORP | $12,305,000 | +73.1% | 110,000 | +46.7% | 5.95% | +56.6% |
| GILD | Buy | GILEAD SCIENCES INC | $11,783,000 | -5.8% | 125,000 | +6.4% | 5.70% | -14.8% |
| XLV | New | SELECT SECTOR SPDR TRput | $8,548,000 | – | 125,000 | +100.0% | 4.13% | – |
| XLRN | Buy | ACCELERON PHARMA INC | $8,376,000 | +1007.9% | 215,000 | +760.0% | 4.05% | +902.0% |
| ESPR | Buy | ESPERION THERAPEUTICS INC NE | $8,088,000 | +164.5% | 200,000 | +60.0% | 3.91% | +139.4% |
| MYL | Buy | MYLAN INC | $5,637,000 | +54.9% | 100,000 | +25.0% | 2.72% | +40.1% |
| XBI | New | SPDR SERIES TRUSTput | $4,662,000 | – | 25,000 | +100.0% | 2.25% | – |
| SNY | Buy | SANOFIsponsored adr | $4,561,000 | +439.1% | 100,000 | +566.7% | 2.20% | +387.6% |
| SHPG | New | SHIRE PLCsponsored adr | $4,251,000 | – | 20,000 | +100.0% | 2.05% | – |
| GWPH | Buy | GW PHARMACEUTICALS PLCads | $4,061,000 | +0.4% | 60,000 | +20.0% | 1.96% | -9.1% |
| THC | Buy | TENET HEALTHCARE CORP | $3,800,000 | +50.6% | 75,000 | +76.5% | 1.84% | +36.3% |
| 5100PS | New | VOLCANO CORPORATION | $3,576,000 | – | 200,000 | +100.0% | 1.73% | – |
| ETRM | Buy | ENTEROMEDICS INC | $3,470,000 | +20.3% | 2,444,000 | +4.3% | 1.68% | +8.9% |
| BIIB | New | BIOGEN IDEC INCput | $3,395,000 | – | 10,000 | +100.0% | 1.64% | – |
| PETX | Buy | ARATANA THERAPEUTICS INC | $3,208,000 | +113.0% | 180,000 | +20.0% | 1.55% | +92.8% |
| IPXL | Buy | IMPAX LABORATORIES INC | $3,168,000 | +167.1% | 100,000 | +100.0% | 1.53% | +141.5% |
| IPXL | New | IMPAX LABORATORIES INCput | $3,168,000 | – | 100,000 | +100.0% | 1.53% | – |
| T107PS | Buy | WRIGHT MED GROUP INC | $3,090,000 | +20.0% | 115,000 | +35.3% | 1.49% | +8.5% |
| NVDQ | Buy | NOVADAQ TECHNOLOGIES INC | $2,909,000 | +83.4% | 175,000 | +40.0% | 1.41% | +66.0% |
| PFE | New | PFIZER INC | $2,336,000 | – | 75,000 | +100.0% | 1.13% | – |
| QDEL | New | QUIDEL CORP | $2,169,000 | – | 75,000 | +100.0% | 1.05% | – |
| OSUR | Buy | ORASURE TECHNOLOGIES INC | $2,028,000 | +60.4% | 200,000 | +14.3% | 0.98% | +45.2% |
| MDT | New | MEDTRONIC INCcall | $1,805,000 | – | 25,000 | +100.0% | 0.87% | – |
| ELOS | Buy | SYNERON MEDICAL LTD | $1,633,000 | +35.9% | 175,000 | +45.8% | 0.79% | +22.9% |
| ACHN | New | ACHILLION PHARMACEUTICALS INcall | $1,531,000 | – | 125,000 | +100.0% | 0.74% | – |
| FLXN | Buy | FLEXION THERAPEUTICS INC | $1,514,000 | +65.8% | 75,000 | +50.0% | 0.73% | +50.0% |
| RAD | New | RITE AID CORP | $1,504,000 | – | 200,000 | +100.0% | 0.73% | – |
| MEIP | New | MEI PHARMA INC | $1,068,000 | – | 250,000 | +100.0% | 0.52% | – |
| XLRN | New | ACCELERON PHARMA INCcall | $974,000 | – | 25,000 | +100.0% | 0.47% | – |
| AXDX | New | ACCELERATE DIAGNOSTICS INC | $960,000 | – | 50,000 | +100.0% | 0.46% | – |
| ACHN | New | ACHILLION PHARMACEUTICALS IN | $919,000 | – | 75,000 | +100.0% | 0.44% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALS | $912,000 | – | 75,000 | +100.0% | 0.44% | – |
| DERM | New | DERMIRA INC | $906,000 | – | 50,000 | +100.0% | 0.44% | – |
| NKTR | New | NEKTAR THERAPEUTICScall | $775,000 | – | 50,000 | +100.0% | 0.38% | – |
| MEIP | New | MEI PHARMA INCcall | $427,000 | – | 100,000 | +100.0% | 0.21% | – |
| KERX | New | KERYX BIOPHARMACEUTICALS INCcall | $425,000 | – | 30,000 | +100.0% | 0.20% | – |
| QDEL | New | QUIDEL CORPcall | $289,000 | – | 10,000 | +100.0% | 0.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 17 | Q1 2018 | 7.5% |
| ULTRAGENYX PHARMACEUTICAL IN | 17 | Q1 2018 | 6.7% |
| MERCK & CO INC NEW | 16 | Q1 2018 | 5.4% |
| CELGENE CORP | 15 | Q4 2017 | 7.9% |
| AERIE PHARMACEUTICALS INC | 15 | Q4 2017 | 3.3% |
| GILEAD SCIENCES INC | 14 | Q1 2017 | 6.7% |
| ESPERION THERAPEUTICS INC NE | 14 | Q1 2018 | 7.8% |
| SUPERNUS PHARMACEUTICALS INC | 14 | Q4 2017 | 2.8% |
| DERMIRA INC | 14 | Q1 2018 | 2.7% |
| AMGEN INC | 13 | Q1 2017 | 6.5% |
View Iguana Healthcare Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-16 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 13F-HR | 2017-05-15 |
| 13F-HR | 2017-02-14 |
| 13F-HR/A | 2016-11-17 |
| 13F-HR | 2016-11-14 |
| 13F-HR/A | 2016-11-04 |
View Iguana Healthcare Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.